Replies to post #10435 on Biotech Values

[si39]

Cox said they are postphoning the mfg scaleup that cost 5 mill to later parr of 05. This sounds like this is on critical path for full-scale rollout of European marketing.
Given how short of cash GTCB is, this is prudent delay to wait for European approval, tradeoff is slower sales ramp up. (already works once since now the answers to EMEA question won't be done by April but July).

[randychub]

GTCB - Pipe - If they do not do a pipe before a decision is made on the approval of Atryn, and the approval is denied, GTCB will have to sell alot of shares to raise the money to continue business.

While the decision to execute a pipe before approval may greatly hurt investors the decision to wait on a pipe, could greatly hurt this company and those who run the company. I think they will be raising money.

Dew, If you care to put another bottle of wine on the line I'll give you a chance to get even. I'll say a pipe is executed before gtcb is given approval.

R

[io_io]

Dew (et al)

Can anyone tell me more about the potential for revenue from the Serum Albuminum product(s) that GTCB is currently marketting ..... and also what is the regulatory position here ?

To me it does look like that, GTCB must give serious consideration to a PIPE prior to EMEA approval. But I would imagine it would be at prices no worse than today's.

TiA